drugset / Trial / NCT00754793
Sinusitis and Facial Pain Disorders Anti-Depression Trial
Phase 4
Terminated
3 enrolled
University of Washington
Forest Laboratories · collabNational Institutes of Health (NIH) · collab
RandomizedSingle-groupDouble-blindTreatment
Summary
The study hypothesis is that the addition of an antidepressant to the standard treatment regimen in patients with both chronic sinusitis and depression or facial pain disorders and depression will decrease the report of chronic sinusitis or facial pain symptom severity. This is a stratified, randomized, double-blind, placebo-controlled study using the drug escitalopram for the treatment of depression in patients experiencing depression and chronic sinusitis or depression and facial pain disorders. It is a 12-week study. Subjects will have a screening visit and then be followed up by phone weekly for four weeks and bi-weekly for 8 weeks.
Timeline
- Start
- 2009-01
- Primary completion
- 2010-08
- Completion
- 2012-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Escitalopram | Small molecule | 20 mg | — |